Aveo takes a big step for­ward as come­back plan de­liv­ers EU OK for ti­vo

Four years af­ter Aveo On­col­o­gy $AVEO was hand­ed a hu­mil­i­at­ing re­jec­tion for its can­cer drug tivozanib, the Cam­bridge, MA-based biotech has turned an im­por­tant cor­ner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER